Total assets Samsung Biologics 2015-2023

Published by Statista Research Department, Apr 16, 2024
In 2023, the total value of assets held by Samsung Biologics amounted to around 16.1 trillion South Korean won. Samsung Biologics is a pharmaceutical company of Samsung Group and produces biopharmaceuticals for global companies. Biotech and health sector are among the key growth engine industries of Samsung Group.

Total assets of Samsung Biologics from 2015 to 2023 (in trillion South Korean won)

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

March 2024

Region

Worldwide, South Korea

Survey time period

2015 to 2023

Special properties

consolidated from 2020 onwards

Supplementary notes

* Consolidated from 2020 onwards.

Figures have been rounded.

1,000 South Korean won equals 0.74 U.S. dollars or 0.69 euro as of April 2024.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Pharma and biotech M&A activity "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharma and biotech M&A activity

Industry overview

5

Number of deals

7

Value of deals

5

Mega-merger: BMS/Celgene

5

2021 outlook

4

Further Content: You might find this interesting as well

Topics

Pharmaceutical industry in Denmark Global pharmaceutical industryPharmaceutical industry in the U.S.Novo NordiskPharmaceutical industry in the UK
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.